cancer types, including bladder cancer [2, 3] . A single nucleotide polymorphism (SNP) in the promoter region of the Mdm2 gene at position 309 ( Mdm2 SNP309; T<=>G) has been broadly investigated because the G allele binds transcriptional activator Sp1 in a more effective way than the T allele, therefore generating higher levels of Mdm2 RNA and protein [4] . This might accelerate tumorigenesis by degrading p53. An influence of this SNP on cancer risk was shown for various tumor types in different populations [5] . In addition, this SNP might also affect the age of disease onset, especially in patients with Li-Fraumeni syndrome, or even gender-specific cancer risk [4, 6, 7] .
Only very inconsistent data are available for the role of the Mdm2 SNP309 in bladder cancer. To date three casecontrol studies have been published. Horikawa et al. [8] reported no influence of this SNP on bladder cancer risk. Onat et al. [9] found an increased tumor risk for the homozygous GG-variant, whereas Gangwar and Mittal [10] reported a reduced bladder cancer risk for individuals with the homozygous GG-variant. Regarding disease outcome, ambiguous data have been published too. While Sanchez-Carbayo et al. [11] reported a poorer overall survival of patients with the homozygous TT-variant compared to patients with a least one risk allele, Horikawa et al. [8] found a longer recurrence-free survival in patients with the homozygous wild-type genotype. Recently, a study focusing on stage pT1 bladder tumors found no influence of the SNP on prognosis [12] .
Interestingly, the Mdm2 SNP309 might also have an influence on the survival of bladder cancer patients treated with chemoradiotherapy. In a study by Shinohara et al. [13] patients with at least one risk allele had an improved cancer-specific survival rate after therapy compared to patients carrying the wild-type allele only. However, this positive effect of the risk allele could not be validated in a second, similar study [14] . To advance the still ongoing discussion of the role of the Mdm2 SNP309 on bladder cancer risk we performed a case-control study including a subset of patients with early disease onset.
Materials and Methods

Patients and Tissue Samples
Two hundred and twenty-four formalin-fixed and paraffin-embedded tissue samples from bladder cancer patients were investigated and compared to 144 samples from a control group of patients without any malignancy acquired at the Department of Urology, University of Regensburg. The tumor group consisted of two subgroups: a consecutive group of bladder cancer patients (n = 113) and a patient cohort with early-onset bladder cancer (less than 45 years of age at diagnosis, n = 111). All patients were Caucasians.
The tumors were diagnosed according to the WHO classification of bladder tumors and staged according the TNM system [15, 16] . All available slides were reinvestigated by one surgical pathologist (A.H.) and all tumors were histologically classified as transitional cell carcinomas. Cases with missing data (e.g. tumor stage, gender) were used for risk evaluation in the case-control study, but were excluded from statistical analyses concerning single parameter tests. All tumors were primary tumors. Characteristics of the study participants are shown in table 1 . Institutional review board approval was obtained for the study.
Tissue Microdissection and DNA Isolation DNA for the study was extracted from normal bladder tissue (microdissection from serial sections) using the High Pure PCR Template Preparation Kit (Roche GmbH, Mannheim, Germany) according to the manufacturer's instructions.
Analysis of Mdm2 SNP309
To analyze the genotype of the Mdm2 SNP309 restriction fragment length polymorphism (RFLP) analysis was performed. When the G allele was present the region of interest contained an Msp A1l site (5 ′ -CMGCKG-3 ′ ). The G allele therefore resulted in digestion of the PCR product (157 bp ≥ 106 + 51 bp) whereas PCR products harboring the T allele in SNP309 remained unaffected (157 bp).
Amplification of Promoter Region and RFLP Analysis
The Mdm2 SNP309 region was amplified by using PCR primers (5-FAM-sense: 5 ′ -CGCGGGAGTTCAGGGTAAAG-3 ′ ; antisense: 5 ′ -CTGAGTCAACCTGCCCACTG-3 ′ [17] ) obtained from . The thermal cycling conditions were as follows: initial denaturation for 3 min at 95 ° C, 35 cycles of denaturation at 95 ° C, annealing at 61 ° C for 1 min, elongation at 72 ° C for 1 min and final primer extension at 72 ° C for 10 min. PCR products were incubated overnight with 5 U Msp A1I (New England Biolabs, Frankfurt am Main, Germany) and 100 μg/ml BSA at 37 ° C in a total volume of 30 μl to ensure complete digestion. Capillary electrophoresis using an ABI PRISM 310 (Applied Biosystems, Foster City, Calif., USA) genetic analyzer was used to separate restriction fragments. Analyses were done using GeneScan ® analysis software. Ten randomly selected cases were also sequenced to verify the RFLP results.
Statistical Analysis
Publicly available software (http://ihg.gsf.de/cgi-bin/hw/hwa1. pl) was used to determine if genotype distribution followed the Hardy-Weinberg equilibrium, whereas χ 2 statistics (two-sided Fisher's exact test or Pearson's where appropriate) were used to evaluate case-control differences in the distribution of genotypes and to analyze associations between clinical or histopathological characteristics and genotype. Statistical analysis was done utilizing the Statistical Package for the Social Sciences (SPSS) version 13.0 (SPSS, Chicago, Ill., USA). p values <0.05 were interpreted as statistically significant.
Results
The genotype distribution followed the Hardy-Weinberg equilibrium in cases (early-onset tumor group, p = 0.342, and consecutive tumor group, p = 0.443) and controls (p = 0.594). Nine cases were randomly selected to verify RFLP analyses: these cases were sequenced and showed a 100% concordance between both methods ( fig. 1 ) .
In order to ensure the usage of our control group as a representative Caucasian cohort we compared the Mdm2 SNP309 distribution from our cohort with published control cohorts from other studies. A very similar allelic distribution was seen in all 4 studies underlining the use of a nonbiased control group in our study ( fig. 2 ).
There were no significant differences in the distribution of the allelic variants of the Mdm2 SNP309 between controls and cases (neither analyzed separately nor analyzed as one cohort; table 2 ; fig. 3 a, b) . Regarding tumor stage, there was a remarkable difference in genotype dis- fig. 4 ). No significant differences in genotype distribution were found for tumor grade, gender and age of the patients (data not shown). In order to enlarge the statistical power of the available analyses on the MDM2 SNP309 we combined all available data from Caucasian bladder cancer studies to perform a meta-analysis. By doing this SNP data from 243 controls and 581 bladder cancer patients were available [9, 11, 12, this study]. The genotype distribution followed the Hardy-Weinberg equilibrium in controls (p = 0.234) and cases (p = 0.444). The distribution of the allelic variants did not differ significantly between controls and cases ( fig. 5 ). There was also no significant difference in the distribution of the G allele between the two cohorts (p = 0.713; OR 0.942, 95% CI 0.686-1.294). Values are n with percentage in parentheses. 1 Results of the consecutive and early-onset tumor groups together. 
Discussion
In the present study we analyzed the distribution of the Mdm2 SNP309 in a Caucasian cohort of bladder cancer patients and a control group without any malignancy. To our knowledge our study comprised the largest cohorts in a Caucasian case-control study to date. Our data showed that the Mdm2 SNP309 did not influence the overall risk for bladder cancer. These data are in line with a study by Horikawa et al. [8] that analyzed large cohorts in a Japanese casecontrol study. In addition, the results from a meta-analysis performed with all available data from studies on Caucasian cohorts further strengthened our data. Contrary to our results, two studies showed contradicting effects of the Gvariant of the SNP. These discrepancies to our study might be explained by a small number of cases analyzed (n = 75) [9] or population-based genetic variation [10] . To date no additional case-control studies have been published and a combined analysis of all the available data might be biased by the different ethnical background of the cohorts.
Of great interest was the study by Sanchez-Carbayo et al. [11] that described an influence of the Mdm2 SNP309 on disease onset in bladder cancer patients, especially in the group of patients with superficial tumors. Our data were contradicting to these findings as we found no association between allelic variants and disease onset, although we analyzed a large subgroup of young bladder cancer patients. These discrepancies might be explained by the fact that the patient cohort from the Sanchez-Carbayo study that showed the age-associated effect in genotype distribution had a mean age of approximately 60 years. As the median age for bladder cancer patients is about 69 years these patients with early disease onset were still within a normal age range [21] . In addition, the study by Sanchez-Carbayo et al. [11] grouped patients with tumor stages pTa and pT1 as patients with superficial disease. This grouping might not reflect the biological background of the tumors, as mRNA expression analyses clearly revealed a very close proximity in the expression profiles of pT1 and muscle-invasive pT2 bladder tumors. The profiles of pTa tumors clearly separated from the invasive tumors [22] . Therefore, a grouping of noninvasive and invasive tumors could bias the results and skew associations between analyzed groups. This grouping should be avoided. The results from our study suggested a higher risk for individuals carrying the risk allele G for developing an invasive bladder tumor. From these data one might suggest that the higher rate of MDM2 transcription caused by the SNP309 G-variant could be causative for this more aggressive phenotype of bladder cancer. However, high expression of MDM2 in bladder tumors was shown to be associated with a better progression-free and a better overall survival of the patients [23] . Moreover, high expression of MDM2 was also associated with low-stage and low-grade bladder tumors [24] . These data strengthen our findings that the G-variant of the SNP309 was not a general risk factor for bladder cancer as a higher MDM2 expression seemed not to support the development of aggressive bladder cancer per se. Functional studies also showed that MDM2 inhibits the hTR promoter and can therefore regulate telomerase activity in bladder cancer cell lines [25] . This regulatory ability of MDM2 is another hint for a quite protective role of MDM2. Nevertheless, high MDM2 levels in tumor cells are a risk factor for an aggressive disease if p53 accumulation is simultaneously present in the cells. Several studies have shown that concurrent MDM2 and p53 overexpression was correlated with disease progression and shorter survival in bladder cancer patients [26, 27] . As p53 accumulation is mainly caused by mutations it might be speculated that high levels of MDM2 inactivate the remaining wild-type p53 in p53-mutated cells, as was suggested for individuals with Li-Fraumeni syndrome [28] . In bladder cancer, p53 mutations were mainly described in carcinoma in situ and invasive tumors, but these alterations were also found in preneoplastic lesions of the urothelium [29, 30] . Therefore, the G-variant of the MDM2 SNP309 might trigger the development of a more aggressive bladder cancer disease as soon as p53 alterations occur, and the combination of both events could promote invasive tumor growth. But as the functional proof for this model has not yet been adduced in bladder cancer, this theory remains speculative.
In conclusion, our study showed that the MDM2 SNP309 has no influence on bladder cancer risk in Caucasians. The G-variant of the SNP was associated with invasive tumor growth and might predispose for the development of a more aggressive phenotype on bladder cancer compared to individuals carrying the T allele only.
